Cannabis Use Frequency and Pain Interference Among People with HIV

Overview

Journal AIDS Care

Publisher Informa Healthcare

Specialty Infectious Diseases

Date 2023 May 18

PMID 37201209

Authors

T D Klepp

T C Heeren

M R Winter

C A Lloyd-Travaglini

K M Magane

E Romero-Rodriguez

T W Kim

A Y Walley

T Mason

R Saitz

Affiliations

Soon will be listed here.

Abstract

Cannabis is often used by people with HIV (PWH) for pain, yet study results are inconsistent regarding whether and how it affects pain. This study examines whether greater cannabis use frequency is associated with lower pain interference and whether cannabis use modifies the association of pain severity and pain interference among 134 PWH with substance dependence or a lifetime history of injection drug use. Multi-variable linear regression models examined the association between past 30-day cannabis use frequency and pain interference. Additional models evaluated whether cannabis use modified the association between pain severity and pain interference. Cannabis use frequency was not significantly associated with pain interference. However, in a model with interaction between cannabis use frequency and pain severity, greater cannabis use frequency attenuated the strength of the association between pain severity and pain interference ( = 0.049). The adjusted mean difference (AMD) in pain interference was +1.13, + 0.81, and +0.05 points for each 1-point increase in pain severity for those with no cannabis use, 15 days of use, and daily use, respectively. These findings suggest that attenuating the impact of pain severity on pain-related functional impairment is a potential mechanism for a beneficial role of cannabis for PWH.

Citing Articles

Associations of discomfort intolerance, discomfort avoidance, and cannabis and alcohol use among persons with chronic pain receiving prescription buprenorphine for opioid use disorder.

Haley D, Stein M, Bendiks S, Karzhevsky S, Pierce C, Dunn A Drug Alcohol Depend. 2024; 265:112472.

PMID: 39488941 PMC: 11588539. DOI: 10.1016/j.drugalcdep.2024.112472.

Self-medication of pain and discomfort with alcohol and other substances by people with HIV infection and substance use disorder: preliminary findings from a secondary analysis.

Stein M, Godersky M, Kim T, Walley A, Heeren T, Winter M AIDS Care. 2023; 36(3):414-424.

PMID: 37909062 PMC: 10922286. DOI: 10.1080/09540121.2023.2275047.

References

Campbell-Sills L, Norman S, Craske M, Sullivan G, Lang A, Chavira D . Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). J Affect Disord. 2008; 112(1-3):92-101. PMC: 2629402. DOI: 10.1016/j.jad.2008.03.014. View

Selim A, Rogers W, Fleishman J, Qian S, Fincke B, Rothendler J . Updated U.S. population standard for the Veterans RAND 12-item Health Survey (VR-12). Qual Life Res. 2008; 18(1):43-52. DOI: 10.1007/s11136-008-9418-2. View

Ellis R, Toperoff W, Vaida F, Van Den Brande G, Gonzales J, Gouaux B . Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2008; 34(3):672-80. PMC: 3066045. DOI: 10.1038/npp.2008.120. View

Shover C, Davis C, Gordon S, Humphreys K . Association between medical cannabis laws and opioid overdose mortality has reversed over time. Proc Natl Acad Sci U S A. 2019; 116(26):12624-12626. PMC: 6600903. DOI: 10.1073/pnas.1903434116. View

Palfai T, Taylor J, Saitz R, Kratzer M, Otis J, Bernstein J . Development of a tailored, telehealth intervention to address chronic pain and heavy drinking among people with HIV infection: integrating perspectives of patients in HIV care. Addict Sci Clin Pract. 2019; 14(1):35. PMC: 6714455. DOI: 10.1186/s13722-019-0165-1. View

Justice A, Holmes W, Gifford A, Rabeneck L, Zackin R, Sinclair G . Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001; 54 Suppl 1:S77-90. DOI: 10.1016/s0895-4356(01)00449-8. View

Atkinson T, Rosenfeld B, Sit L, Mendoza T, Fruscione M, Lavene D . Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). J Pain Symptom Manage. 2010; 41(3):558-65. PMC: 3062715. DOI: 10.1016/j.jpainsymman.2010.05.008. View

Fleet J, Dixon S, Kuwornu P, Dev V, Montero-Odasso M, Burneo J . Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study. PLoS One. 2018; 13(3):e0193134. PMC: 5851574. DOI: 10.1371/journal.pone.0193134. View

Campbell G, Hall W, Peacock A, Lintzeris N, Bruno R, Larance B . Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 2018; 3(7):e341-e350. PMC: 6684473. DOI: 10.1016/S2468-2667(18)30110-5. View

10.

Ventura A, Winter M, Heeren T, Sullivan M, Walley A, Holick M . Lifetime and recent alcohol use and bone mineral density in adults with HIV infection and substance dependence. Medicine (Baltimore). 2017; 96(17):e6759. PMC: 5413268. DOI: 10.1097/MD.0000000000006759. View

11.

Fairchild A, MacKinnon D . A general model for testing mediation and moderation effects. Prev Sci. 2008; 10(2):87-99. PMC: 2908713. DOI: 10.1007/s11121-008-0109-6. View

12.

Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

13.

Hartzler B, Dombrowski J, Crane H, Eron J, Geng E, Mathews W . Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States. AIDS Behav. 2016; 21(4):1138-1148. PMC: 6089366. DOI: 10.1007/s10461-016-1584-6. View

14.

Saitz R, Mesic A, Ventura A, Winter M, Heeren T, Sullivan M . Alcohol Consumption and Bone Mineral Density in People with HIV and Substance Use Disorder: A Prospective Cohort Study. Alcohol Clin Exp Res. 2018; . PMC: 6281811. DOI: 10.1111/acer.13801. View

15.

Bruce R, Merlin J, Lum P, Ahmed E, Alexander C, Corbett A . 2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV. Clin Infect Dis. 2017; 65(10):e1-e37. PMC: 5848240. DOI: 10.1093/cid/cix636. View

16.

Valeri L, VanderWeele T . Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods. 2013; 18(2):137-50. PMC: 3659198. DOI: 10.1037/a0031034. View

17.

Merlin J, Long D, Becker W, Cachay E, Christopoulos K, Claborn K . Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr. 2018; 79(1):77-82. PMC: 6092197. DOI: 10.1097/QAI.0000000000001741. View

18.

Eibach L, Scheffel S, Cardebring M, Lettau M, Celik M, Morguet A . Cannabidivarin for HIV-Associated Neuropathic Pain: A Randomized, Blinded, Controlled Clinical Trial. Clin Pharmacol Ther. 2020; 109(4):1055-1062. DOI: 10.1002/cpt.2016. View

19.

Lee M, Silverman S, Hansen H, Patel V, Manchikanti L . A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011; 14(2):145-61. View

20.

Hill K . Medical Use of Cannabis in 2019. JAMA. 2019; 322(10):974-975. DOI: 10.1001/jama.2019.11868. View